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The activity of ZD 1839 on brain metastases (BM) from Non-Small-Cell Lung Cancer (NSCLC) is unknown. We report four cases of
BM responding to ZD 1839 theraphy.
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ZD 1839 (gefitinib, Iressa; AstraZeneca Pharmaceuticals, Wilming-
ton, DE, USA) is an orally active, selective epidermal growth factor
receptor (EGFR) tyrosine-kinase inhibitor (TKI), which demon-
strated antitumour activity in vitro and in vivo (Ciardiello et al,
2000). In pretreated non-small-cell lung cancer (NSCLC) patients,
phase I and II studies demonstrated that ZD 1839 is active and well
tolerated, with a response rate of about 10–15% (Kris et al, 2000,
2002; Fukuoka et al, 2002). The presence of brain metastases (BM)
has been considered as an exclusion criterion in all trials
conducted so far (Kris et al, 2000, 2002; Fukuoka et al, 2002;
Giaccone et al, 2002; Johnson et al, 2002). Therefore, the activity of
ZD 1839 on BM is unknown. Since January 2001, we participated in
the ZD 1839 compassionate use programme, in which pretreated fit
NSCLC patients were candidates to receive ZD 1839 at 250mg daily
dose. Compassionate use programme criteria do not exclude
patients with BM. Here, we report four cases of BM from NSCLC
patients responding to ZD 1839 therapy.
Patients were 53, 54, 55, and 65 years old, two male and two
female patients. Histology was adenocarcinoma (two cases),
squamous cell carcinoma (one case) and bronchiolo-alveolar
carcinoma (one case). All patients developed BM in the presence
of extracranial disease. All patients had received a first-line
platinum-based chemotherapy, and two patients were treated with
whole-brain radiotherapy (WBRT) for BM terminated at least 3
months before starting ZD 1839, with evidence of brain disease
progression when therapy with ZD 1839 was started. In the other
two patients, ZD 1839 was begun for appearance of asymptomatic
BM and progressive disease on the extracranial sites. After 3
months of ZD 1839 therapy, all the patients had a partial response
both in the brain and in the extracranial sites (Figure 1). At the
time of this analysis, two patients discontinued the treatment after
8 and 15 months for disease progression, while two patients are
still on treatment with no evidence of treatment failure after 6þ
and 11þ months. ZD 1839 therapy was generally well tolerated,
with skin toxicity recorded in three patients (two patients grade 1
and one patient grade 2). All four patients experienced sympto-
matic improvement while on treatment.
This report suggests that ZD 1839 is effective in NSCLC patients
with pretreated BM, but further trials are needed to better evaluate
the role of this compound in these patients. Based on our results,
the presence of BM should not be considered an exclusion
criterion in future TKI studies.
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Figure 1 Case 4: Brain CT-scan at baseline (A) and after 3 months of
ZD1839 therapy (B). Brain metastasis from NSCLC responding to ZD
1839 therapy. This patient has been pretreated with three lines of
chemotherapy including platinum and taxanes, and received ZD 1839 after
whole-brain radiotherapy failure. Received 25 February 2003; accepted 21 April 2003
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